Hyman Phelps and McNamara
Andrew J. Hull
Photo of Andrew J. Hull

(202) 737-4296
Download Vcard

J.D., summa cum laude, Regent University School of Law
B.A., summa cum laude, Government, Patrick Henry College

Bar Admissions
District of Columbia
U.S. District Court for the District of Columbia
U.S. Court of Appeals for the District of Columbia Circuit

Printer Friendly Page

Andrew J. Hull represents clients on matters related to administrative, civil, and criminal investigations and proceedings conducted by the DOJ, DEA, FDA, and state authorities under the federal Controlled Substances Act (CSA), the Federal Food, Drug, and Cosmetic Act, and related state laws and regulations. He also advises clients on compliance with federal and state laws and regulations related to the manufacturing, distributing, and dispensing of controlled substances and prescription drugs, particularly under the federal CSA and the Drug Supply Chain Security Act.

Prior to joining the firm, Mr. Hull served as the law clerk to the DEA’s Chief Administrative Law Judge (ALJ), John J. Mulrooney, II, a position he was awarded through the DOJ’s Attorney General’s Honors Program. As a law clerk, he co-authored with Judge Mulrooney the first in-depth primer for practitioners and pharmacies involved in administrative proceedings and hearings before the DEA, titled Drug Diversion Administrative Revocation and Application Hearings for Medical and Pharmacy Practitioners: A Primer for Navigating Murky, Drug-Infested Waters.

At law school, Mr. Hull served as the editor-in-chief of his school’s law review, and he is the author of numerous publications.

Related Experience
• Represent clients in civil matters, including motions for temporary restraining orders and preliminary injunctions.
• Assist clients in responding to criminal subpoenas and internal investigations; manage related large-volume document productions.

Controlled Substances and Prescription Drugs
• Counsel clients regarding licensing, security, recordkeeping, reporting, and related requirements for manufacturers, distributors, and pharmacies.
• Interact with state regulators, such as pharmacy boards and controlled substance authorities, regarding client-specific issues.

Articles / Publications    -    see fewer articles
•  Court deals blow to mysteriously named whistleblower, blowing off precedent,  October 17, 2017

•  A Practical Roadmap for Transitioning State Licenses for Sales of Prescription Drugs and Devices in Corporate Transactions,  November, 2016

•  Ninth Circuit Confounds Practice of Medicine and Off-Label Use Issues,  November 1, 2016

•  A Matter of Substantial Discretion: A Recent Rift between DEA and Its ALJs Could Significantly Impact Registrants,  November/December 2015

•  Quality Egg and Jail Time for a Park Doctrine Prosecution,  May 6, 2015

•  A Warning Letter on FDA's Expansive Interpretation of Its Facilities - Inspection Authority,  March 13, 2015

•  Prior Restraint and the Union Political Spech Opt-Out Requirements,  March 1, 2015

•  Drug Diversion Administrative Revocation and Application Hearings for Medical and Pharmacy Practitioners,  February 28, 2015

•  Unearthing Mansfield's Rule: Analysing the Appropriateness of Federal Rule of Evidence 606(B) in Light of the Common Law Tradtition,  December 1, 2014

•  Complete or Partial Accommodation: An Analysis of the Federal Circuit Split Over the Duty of the Employer to Reasonably Accommodate the Religious,  April 1, 2014

Blog Posts    -    see fewer blog entries
•  Sixth Circuit Affirms Dismissal of Off-Label Promotion FCA Case for Lack of Rule 9(b) Specificity,  November 5, 2017
•  Judicial Efficiency: DEA’s Expanding Use of Summary Dispositions to Narrow the Opportunity for an Administrative Hearing,  October 15, 2017
•  Court Deals Blow to Mysteriously Named Whistleblower, and Blows off Precedent,  September 27, 2017
•  Fifth Circuit Upholds Summary Judgment for Solvay Pharmaceuticals in Off-Label and Anti-Kickback FCA Case,  September 20, 2017
•  Celgene Pays $280m in False Claims Act Case in Which U.S. Did Not Intervene,  August 1, 2017
•  A Call to Duty: DEA Practitioner Registrants Beware—DEA Wants You!,  July 10, 2017
•  FDA: Protecting the Integrity of Horse Racing Since 1906,  June 19, 2017
•  DEA Administrative Decisions Update: Has DEA Established New Grounds for Summary Disposition?,  May 24, 2017
•  DEA Administrative Decisions Update: What’s Prescribed in Vegas . . . Has Got to Stay in Vegas,  May 15, 2017
•  DEA Administrative Decisions Update: Sex, Drugs, and . . . Rocky Agency Precedent,  April 11, 2017
•  DEA Administrative Decisions Update: (Un)official Notice Revisited,  February 22, 2017
•  DEA Administrative Hearings Update: Rethinking DEA’s Summary Disposition Power in “Loss of State Authority” Cases,  February 15, 2017
•  First Circuit Rejects Fraud-on-FDA Allegations Under False Claims Act,  January 16, 2017
•  DEA Administrative Hearings: “Open to the Public” Requires Notice to the Public,  October 26, 2016j
•  DEA Administrative Decisions Update: DEA’s Questionable Practice of (Un)official Notice,  October 25, 2016
•  Court Rejects Prosecution of Pharmacists Due to Lack of Fair Notice in FDC Act,  October 10, 2016
•  Ninth Circuit Confounds Practice of Medicine and Off-Label Use Issues,  September 28, 2016
•  FDA To Hold Two-Day Hearing on Off-Label Communications,  September 1, 2016
•  Federal Circuit Says BPCIA’s 180-Day Post-Licensure Notice Is Mandatory and Enforceable by Preliminary Injunction,  July 7, 2016
•  FDA’s Permanent Injunction Authority: Is There a Crack in FDA’s Resolve to Shut Down a Facility’s Operations?,  April 6, 2016